Evolus Revenue 2016-2019 | EOLS
Evolus revenue from 2016 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
| Evolus Annual Revenue (Millions of US $) |
|
|---|---|
| 2018 | $ |
| 2017 | $ |
| 2016 | $ |
| 2015 | $ |
| Evolus Quarterly Revenue (Millions of US $) |
|
|---|---|
| Q2 2019 | $2 |
| Q1 2019 | |
| Q4 2018 | |
| Q3 2018 | |
| Q2 2018 | |
| Q1 2018 | |
| Q4 2017 | |
| Q3 2017 | |
| Q2 2017 | |
| Q1 2017 | |
| Q4 2016 | |
| Q4 2015 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.411B | $0.000B |
| Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $145.598B | 26.57 |
| Medtronic (MDT) | Ireland | $145.585B | 20.43 |
| Stryker (SYK) | United States | $80.642B | 27.89 |
| Boston Scientific (BSX) | United States | $53.170B | 25.79 |
| Baxter (BAX) | United States | $44.852B | 27.20 |
| EssilorLuxottica Societe Anonyme (ESLOY) | France | $32.725B | 0.00 |
| Zimmer Biomet Holdings (ZBH) | United States | $28.438B | 18.20 |
| Coloplast (CLPBY) | Denmark | $25.747B | 41.10 |
| Lonza Group Ag (LZAGY) | Switzerland | $25.481B | 0.00 |
| Terumo (TRUMY) | Japan | $24.495B | 30.57 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $20.928B | 0.00 |
| ResMed (RMD) | United States | $18.924B | 36.06 |
| Sunny Optical Technology (SNPTF) | China | $16.014B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $10.234B | 54.86 |
| Insulet (PODD) | United States | $9.431B | 558.86 |
| Perrigo (PRGO) | Ireland | $7.400B | 13.63 |
| Canopy Growth (CGC) | Canada | $7.222B | 0.00 |
| Hill-Rom Holdings (HRC) | United States | $6.830B | 20.36 |
| Haemonetics (HAE) | United States | $6.455B | 48.71 |
| William Demant Holdings (WILYY) | Denmark | $5.988B | 0.00 |
| GN STORE NORD (GNNDY) | Denmark | $5.344B | 27.61 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $4.296B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $4.002B | 0.00 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $3.680B | 0.00 |
| Neogen (NEOG) | United States | $3.490B | 58.40 |
| NuVasive (NUVA) | United States | $3.398B | 27.09 |
| ICU Medical (ICUI) | United States | $3.237B | 21.00 |
| Hutchison China MediTech (HCM) | Hong Kong, SAR China | $2.634B | 0.00 |
| Quidel (QDEL) | United States | $2.510B | 24.93 |
| Agios Pharmaceuticals (AGIO) | United States | $1.982B | 0.00 |
| National Vision Holdings (EYE) | United States | $1.877B | 40.51 |
| Cardiovascular Systems (CSII) | United States | $1.670B | 0.00 |
| Aphria (APHA) | $1.242B | 0.00 | |
| VAREX IMAGING (VREX) | United States | $1.124B | 25.90 |
| AtriCure (ATRC) | United States | $1.059B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.867B | 14.10 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.854B | 21.78 |
| NanoString Technologies (NSTG) | United States | $0.787B | 0.00 |
| Omeros (OMER) | United States | $0.759B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.734B | 19.29 |
| PetIQ (PETQ) | United States | $0.725B | 17.13 |
| LeMaitre Vascular (LMAT) | United States | $0.689B | 40.82 |
| Cerus (CERS) | United States | $0.624B | 0.00 |
| Surmodics (SRDX) | United States | $0.621B | 118.00 |
| MacroGenics (MGNX) | United States | $0.560B | 0.00 |
| Quanterix (QTRX) | United States | $0.548B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.530B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.523B | 24.23 |
| Owens & Minor (OMI) | United States | $0.459B | 13.76 |
| Meridian Bioscience (VIVO) | United States | $0.427B | 13.32 |
| Utah Medical Products (UTMD) | United States | $0.354B | 25.91 |
| Zynex (ZYXI) | United States | $0.346B | 36.76 |
| BioLife Solutions (BLFS) | United States | $0.339B | 104.19 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.327B | 0.00 |
| Bovie Medical (APYX) | United States | $0.234B | 0.00 |
| United Health Products (UEEC) | United States | $0.208B | 0.00 |
| Vapotherm (VAPO) | United States | $0.177B | 0.00 |
| Repro-Med Systems (REPR) | United States | $0.158B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.153B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.147B | 0.00 |
| Female Health (VERU) | United States | $0.138B | 0.00 |
| Fonar (FONR) | United States | $0.133B | 9.32 |
| InfuSystems Holdings (INFU) | United States | $0.127B | 0.00 |
| Liberty Health Sciences (LHSIF) | Canada | $0.104B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.097B | 0.00 |
| Chimerix (CMRX) | United States | $0.088B | 0.00 |
| Nephros (NEPH) | United States | $0.087B | 0.00 |
| United-Guardian (UG) | United States | $0.084B | 19.82 |
| MTech Acquisition (KERN) | United States | $0.063B | 0.00 |
| MRI Interventions (MRIC) | United States | $0.058B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.053B | 0.00 |
| ImmuCell (ICCC) | United States | $0.040B | 0.00 |
| Surface Oncology (SURF) | United States | $0.039B | 0.00 |
| Senestech (SNES) | United States | $0.023B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.020B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.018B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.013B | 0.00 |
| Myomo (MYO) | United States | $0.010B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.010B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.007B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.005B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.003B | 0.00 |
